Complete financial analysis of Cell MedX Corp. (CMXC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cell MedX Corp., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- ENDI Corp. (ENDI) Income Statement Analysis – Financial Results
- Rhythm Co.,Ltd. (7769.T) Income Statement Analysis – Financial Results
- Fifth District Savings Bank (FDSB) Income Statement Analysis – Financial Results
- P.C.B. Technologies Ltd (PCBT.TA) Income Statement Analysis – Financial Results
- AFC Gamma, Inc. (AFCG) Income Statement Analysis – Financial Results
Cell MedX Corp. (CMXC)
About Cell MedX Corp.
Cell MedX Corp., a biotech company, focuses on the discovery, development, and commercialization of therapeutic and non-therapeutic products for patients with diabetes, Parkinson's disease, high blood pressure, neuropathy, and kidney functions. It develops and manufactures eBalance Pro System for professional use by healthcare practitioners in a clinical setting; and eBalance Home System for home use for general wellness and pain management treatment, which are controlled by the eBalance Console that acts as the central controller for three pre-programmed microcurrent algorithms, including wellness, pain management, and dual. The company was formerly known as Sports Asylum, Inc. and changed its name to Cell MedX Corp. in September 2014. Cell MedX Corp. was incorporated in 2010 and is based in Carson City, Nevada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 2.76K | 6.07K | 6.76K | 95.82K | 0.00 | 0.00 | 6.22K | 36.56K | 42.62K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 2.28K | 2.03K | 3.24K | 10.24K | 580.00 | 0.00 | 4.05K | 28.42K | 26.56K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 483.00 | 4.03K | 3.52K | 85.59K | -580.00 | 0.00 | 2.17K | 8.14K | 16.06K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 17.49% | 66.50% | 52.09% | 89.32% | 0.00% | 0.00% | 34.87% | 22.27% | 37.69% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 22.54K | 89.22K | 150.71K | 229.58K | 393.22K | 261.91K | 418.32K | 297.04K | 650.38K | 177.87K | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 290.89K | 358.92K | 523.87K | 453.83K | 675.09K | 407.72K | 1.12M | 802.44K | 1.44M | 779.51K | 18.53K | 12.64K | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 261.00 | 53.79K | 4.44K | 0.00 | 0.00 | 0.00 | 172.65K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 290.89K | 358.92K | 523.87K | 454.09K | 728.88K | 407.72K | 1.12M | 802.44K | 1.44M | 779.51K | 18.53K | 12.64K | 15.86K | 0.00 |
| Other Expenses | 0.00 | 81.11K | 1.15K | 2.43K | 1.85K | 580.00 | 881.95K | 123.05K | 20.60K | 1.96K | 0.00 | 12.64K | 0.00 | 0.00 |
| Operating Expenses | 313.43K | 448.14K | 675.73K | 686.11K | 1.12M | 670.21K | 1.54M | 1.22M | 2.11M | 959.33K | 18.53K | 12.64K | 15.86K | 0.00 |
| Cost & Expenses | 313.43K | 450.42K | 677.76K | 689.35K | 1.13M | 670.21K | 1.54M | 1.23M | 2.14M | 985.89K | 18.53K | 12.64K | 15.86K | 0.00 |
| Interest Income | 0.00 | 47.38K | 25.69K | 32.02K | 21.07K | 16.72K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 47.38K | 25.69K | 32.02K | 21.07K | 16.72K | 11.23K | 52.03K | 37.86K | 95.11K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 268.35K | 1.15K | 1.15K | 2.43K | 1.85K | 580.00 | 153.36K | 123.05K | 20.60K | 1.96K | 18.53K | 12.64K | 0.00 | 0.00 |
| EBITDA | 0.00 | -447.66K | -670.55K | -721.92K | -1.04M | -669.63K | -1.38M | -1.07M | -2.08M | -1.01M | -18.53K | -12.64K | -15.86K | 0.00 |
| EBITDA Ratio | 0.00% | -16,207.75% | -11,056.03% | -7,156.52% | -1,081.68% | 0.00% | 0.00% | -17,641.64% | -5,699.73% | -2,208.40% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -313.43K | -445.38K | -671.69K | -486.36K | -1.04M | -889.26K | -1.54M | -1.20M | -2.10M | -1.03M | -18.53K | -12.64K | -15.86K | 0.00 |
| Operating Income Ratio | 0.00% | -16,125.24% | -11,074.91% | -7,192.52% | -1,083.60% | 0.00% | 0.00% | -19,251.00% | -5,747.94% | -2,421.56% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 170.94K | -47.38K | -25.69K | -228.25K | -54.35K | -236.35K | -11.23K | -33.14K | -34.89K | -26.56K | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -142.49K | -495.04K | -697.38K | -910.84K | -1.09M | -905.98K | -1.55M | -1.25M | -2.14M | -1.03M | -18.53K | -12.64K | -15.86K | 0.00 |
| Income Before Tax Ratio | 0.00% | -17,923.32% | -11,498.42% | -13,469.92% | -1,140.32% | 0.00% | 0.00% | -20,087.56% | -5,851.51% | -2,421.56% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -170.17K | 25.69K | 228.25K | 21.07K | 16.72K | -153.36K | 52.03K | 37.86K | 88.90K | -18.53K | -12.64K | 0.00 | 0.00 |
| Net Income | -142.49K | -495.04K | -723.07K | -1.14M | -1.11M | -922.70K | -1.55M | -1.25M | -2.14M | -1.03M | -18.53K | -12.64K | -15.86K | 0.00 |
| Net Income Ratio | 0.00% | -17,923.32% | -11,921.93% | -16,845.39% | -1,162.30% | 0.00% | 0.00% | -20,087.56% | -5,851.51% | -2,421.56% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.00 | -0.01 | -0.01 | -0.02 | -0.02 | -0.02 | -0.04 | -0.03 | -0.07 | -0.03 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | -0.01 | -0.01 | -0.02 | -0.02 | -0.02 | -0.04 | -0.03 | -0.07 | -0.03 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 297.24M | 62.92M | 62.80M | 58.76M | 53.48M | 44.28M | 42.31M | 36.86M | 31.00M | 31.00M | 31.00M | 31.00M | 30.27M | 30.00M |
| Weighted Avg Shares Out (Dil) | 161.01M | 62.92M | 62.80M | 58.76M | 53.48M | 44.28M | 42.31M | 36.86M | 31.00M | 31.00M | 31.00M | 31.00M | 30.27M | 30.00M |
StimCell Energetics Inc. (Formerly "Cell MedX Corp.") Announces Major Corporate Updates and Rebranding
VANCOUVER, BC / ACCESSWIRE / November 4, 2024 / StimCell Energetics Inc. (formerly "Cell MedX Corp.") (OTC PINK:CMXC) ("StimCell", or the "Company") a biotech company targeting cellular energy to promote anti-aging, longevity and general wellness, is pleased to announce a...
Cell MedX Corp. Closes Private Placement Financing
Vancouver, British Columbia--(Newsfile Corp. - March 19, 2024) - Cell MedX Corp. (OTC Pink: CMXC) ("Cell MedX", or the "Company") a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote anti-aging and general...
Cell MedX Corp. Announces Resignation of Director
Vancouver, British Columbia--(Newsfile Corp. - February 28, 2024) - Cell MedX Corp. (OTC Pink: CMXC) ("Cell MedX", or the "Company") a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote anti-aging and general...
Cell MedX Corp. Appoints Dr. George Adams as Chairman of the Board
Vancouver, British Columbia--(Newsfile Corp. - February 26, 2024) - Cell MedX Corp. (OTC Pink: CMXC) ("Cell MedX", or the "Company") a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote anti-aging and general...
Cell MedX Corp. Announces New CEO and Directors and Debt Settlement
Vancouver, British Columbia--(Newsfile Corp. - December 19, 2023) - Cell MedX Corp. (OTC Pink: CMXC) ("Cell MedX" or the "Company"), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, announces...
Cell MedX Corp. Announces Full Revocation of British Columbia Cease Trade Order
Vancouver, British Columbia--(Newsfile Corp. - November 27, 2023) - Cell MedX Corp. ("Cell MedX" or the "Company") (OTC Pink: CMXC) announces that on November 22, 2023, the British Columbia Securities Commission (the "BCSC") issued an order revoking the Cease Trade...
Cell MedX Corp. Appoints Audit Committee and Accepts Resignation of Chief Operating Officer
Vancouver, British Columbia--(Newsfile Corp. - November 9, 2023) - Cell MedX Corp. (OTC Pink: CMXC) ("Cell MedX" or the "Company"), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is...
Source: https://incomestatements.info
Category: Stock Reports